Twist Bioscience Corp (NASDAQ:TWST) has earned an average broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and three have given a strong buy recommendation to the company. Twist Bioscience’s rating score has improved by 10.2% from three months ago as a result of various analysts’ upgrades and downgrades.

Brokerages have set a one year consensus target price of $29.50 for the company and are predicting that the company will post ($0.83) EPS for the current quarter, according to Zacks. Zacks has also given Twist Bioscience an industry rank of 48 out of 256 based on the ratings given to related companies.

TWST has been the subject of a number of recent research reports. Zacks Investment Research downgraded Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. Evercore ISI restated an “in-line” rating and set a $31.00 price objective (down from $40.00) on shares of Terex in a research note on Friday, May 31st.

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in Twist Bioscience during the 4th quarter worth $7,782,000. American International Group Inc. acquired a new position in Twist Bioscience during the 4th quarter worth $77,000. Asymmetry Capital Management L.P. acquired a new position in Twist Bioscience during the 1st quarter worth $550,000. D. E. Shaw & Co. Inc. acquired a new position in Twist Bioscience during the 4th quarter worth $1,039,000. Finally, Norges Bank acquired a new position in Twist Bioscience during the 4th quarter worth $1,155,000. Institutional investors own 18.50% of the company’s stock.

Shares of NASDAQ TWST traded up $1.38 during trading on Monday, reaching $33.98. The stock had a trading volume of 287,300 shares, compared to its average volume of 213,490. Twist Bioscience has a one year low of $12.38 and a one year high of $34.46. The company has a current ratio of 6.51, a quick ratio of 6.27 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $1.06 billion and a PE ratio of -1.33. The stock has a 50 day simple moving average of $28.81.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Tuesday, April 30th. The company reported ($0.93) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.03) by $0.10. The company had revenue of $13.56 million for the quarter, compared to the consensus estimate of $11.88 million. On average, sell-side analysts expect that Twist Bioscience will post -3.65 earnings per share for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Read More: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Twist Bioscience (TWST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.